SolasCure
SolasCure is dedicated to transforming chronic wound care through innovative therapeutic solutions. The company is at the forefront of developing Aurase Wound Gel, a breakthrough enzymatic debrider designed to return chronic wounds to healing. SolasCure aims to shift the paradigm in wound care by providing high-impact, safe, and effective treatments that address the underlying causes of wounds rather than just managing symptoms. With a strong focus on research and development, SolasCure is committed to improving the health and wellbeing of patients worldwide.
Industries
Nr. of Employees
small (1-50)
SolasCure
Wellington House, East Road, Cambridge, Cambridgeshire, CB1 1BH
Products
Aurase Wound Gel
A topical hydrogel formulation delivering a recombinant protease-based enzyme designed to enzymatically debride non-viable wound tissue, disrupt biofilm and support wound-bed preparation across clinic, hospital and community settings.
Aurase Wound Gel
A topical hydrogel formulation delivering a recombinant protease-based enzyme designed to enzymatically debride non-viable wound tissue, disrupt biofilm and support wound-bed preparation across clinic, hospital and community settings.
Expertise Areas
- Clinical trial management and execution
- Enzymatic therapeutic development for wound care
- Recombinant protein expression and production
- Hydrogel biomaterial formulation for topical delivery
Key Technologies
- Recombinant protein expression
- Protease-based enzymatic debridement
- Hydrogel delivery systems
- pH-responsive enzyme mechanisms
Key People
Investors
Innovate UK
$518,317 funded.
Announced on 2024-03-20.
European Innovation Council
Announced on 2023-10-30.
Seneca Partners
$13,403,144 funded.
Announced on 2023-03-27.
Series A - SolasCure
$20,769,755 funded.
Announced on 2021-08-09.
EIC Accelerator
Announced on 2021-05-17.
Seed Round - SolasCure
Announced on 2018-08-20.
Innovate UK
$518,317 funded.
Announced on 2024-03-20.
European Innovation Council
Announced on 2023-10-30.
Seneca Partners
$13,403,144 funded.
Announced on 2023-03-27.
Series A - SolasCure
$20,769,755 funded.
Announced on 2021-08-09.
EIC Accelerator
Announced on 2021-05-17.
Seed Round - SolasCure
Announced on 2018-08-20.
News & Updates
SolasCure has partnered with the U.S. Army Institute of Surgical Research to evaluate Aurase Wound Gel for treating infected wounds in combat scenarios. The collaboration aims to assess the gel's enzymatic debridement properties in reducing wound biofilm production and bioburden.
This article discusses the potential of enzymes in wound care, highlighting the benefits of Aurase Wound Gel in providing effective, painless debridement and improving healing rates for chronic wounds.
SolasCure was selected for the Innovate UK & TMC Innovation Accelerator Program in partnership with Texas Medical Center in 2024.
In 2024, SolasCure received the Biomedical Catalyst Grant from Innovate UK, the UK's innovation agency.
SolasCure was awarded the EIC Accelerator Grant by the European Innovation Council in 2023.
SolasCure was recognized as a Life Sciences Innovator in 2023 by the UK Department for Business and Trade.
SolasCure has partnered with the U.S. Army Institute of Surgical Research to evaluate Aurase Wound Gel for treating infected wounds in combat scenarios. The collaboration aims to assess the gel's enzymatic debridement properties in reducing wound biofilm production and bioburden.
This article discusses the potential of enzymes in wound care, highlighting the benefits of Aurase Wound Gel in providing effective, painless debridement and improving healing rates for chronic wounds.
SolasCure was selected for the Innovate UK & TMC Innovation Accelerator Program in partnership with Texas Medical Center in 2024.
In 2024, SolasCure received the Biomedical Catalyst Grant from Innovate UK, the UK's innovation agency.
SolasCure was awarded the EIC Accelerator Grant by the European Innovation Council in 2023.
SolasCure was recognized as a Life Sciences Innovator in 2023 by the UK Department for Business and Trade.